TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed diagnosis of recurrent or refractory high-grade glioma (anaplastic astrocytoma, WHO grade III; or glioblastoma, WHO grade IV)~* Supratentorial localization~* No more than two chemotherapy regimens including radiochemotherapy since primary diagnosis~* Eligible for either TMZ or PCV treatment~* Recovery from acute toxicity caused by any previous therapy~* Adequate organ functions~* KPS at least 70%~Exclusion Criteria:~* Tumor surgery within 2 weeks prior to study entry~* Radiation therapy within 8 weeks prior to study entry~* Chemotherapy within 4 weeks prior to study entry (nitrosureas: 6 weeks)~* No more than 3 mg/day dexamethasone (or equivalent) at baseline~* Prior TGF-beta targeted therapy or tumor vaccination~* Baseline MRI shows mass effect~* Known active infection with HIV, HBV, or HCV; acute viral, bacterial, or fungal infection~* Significant psychiatric disorders/legal incapacity or a limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AP 12009 10 µM (Type: EXPERIMENTAL): None
- AP 12009 80 µM (Type: EXPERIMENTAL): None
- Chemotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed newly diagnosed stage II or III neuroblastoma or ganglioneuroblastoma~  * Unresectable disease~* No MYCN amplification (i.e., fewer than 10 copies)~* No metastases to bone marrow~* No radiological bone lesions in skeleton~PATIENT CHARACTERISTICS:~Age:~* Under 12 months at diagnosis~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No evidence of liver disease by ultrasound~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with confirmed SCA who participated in the NOHARM study of hydroxyurea at the Mulago Hospital Sickle Cell Clinic (MHSCC), will be eligible for the MTD study after completing both 12-months of blinded study treatment and then an additional 12-months of open-label hydroxyurea for the second year of the study.~* The age range for enrollment into NOHARM, which began in 2014, was 1-4 years. Therefore, the children who will be enrolled in the follow up MTD study will be 3-6 years of age.~Exclusion Criteria:~* Not willing to come for all scheduled clinical visits or accept randomization

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 72 Months
- Healthy Volunteers: f

Study Arms:
- MTD Dose Escalation (Type: EXPERIMENTAL): Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
- Fixed Dose (Type: ACTIVE_COMPARATOR): Fixed dose of Hydroxyurea, 20 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal weight, overweight and obese subjects with BMI\> 18 Kg/m2 residing in Olmsted County, MN: Otherwise healthy individuals who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than hyperglycemia not requiring medical therapy) and unstable psychiatric disease.~* Age: 18-65 years~* Gender: Men or women. Women of childbearing potential will have negative pregnancy test within 48 h of enrollment and before each radiation exposure.~Exclusion Criteria:~* Weight exceeding 300 pounds or 137 kilograms (due to limitations regarding SPECT imaging studies).~* Abdominal surgery other than appendectomy, Caesarian section or tubal ligation.~* Positive history of chronic gastrointestinal diseases, systemic disease that could affect gastrointestinal motility or use of medications that may alter gastrointestinal motility, appetite or absorption e.g., orlistat (Xenical\&#61650;).~* Significant psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Scale \[HADS\] self-administered alcoholism screening test (substance abuse) and the questionnaire on eating and weight patterns (binge eating disorders and bulimia). If such a dysfunction is identified by a HADS score \>8 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.~* Intake of medication, whether prescribed or OTC medication (except multivitamins) within 7 days of the study. Exceptions are birth control pill, estrogen replacement therapy, and thyroxine replacement.~* Concomitant use of MAOI inhibitors and other centrally acting appetite suppressants (since this would make them ineligible for sibutramine treatment).~* Hypersensitivity to sibutramine (since this would make them ineligible for sibutramine treatment).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): placebo tablet
- 2 (Type: EXPERIMENTAL): sibutramine
- 3 (Type: EXPERIMENTAL): sibutramine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Collision Warning Device for Blind and Visually Impaired

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Blindness (or very limited vision with visual acuity no better than counting fingers),~* Or severe peripheral field loss / tunnel vision (≤ 40° remaining visual field) with visual acuity of at least 20/200,~* Or homonymous hemianopia with visual acuity of at least 20/200;~* Able to walk independently either with or without mobility aids such as a long cane or guide dog (but without the aid of a sighted guide);~* Reports at least minor bumps or collisions within the last 3 months;~Exclusion Criteria:~* Currently participating in a mobility training program~* Diagnosed dementia~* Significant cognitive decline~* Participants with hemianopia will be excluded if they have hemianopia for less than 3 months and/or have spatial neglect

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman \> 18 years old~* Patient with wAMD previously treated with ranibizumab (for less than 12 months before initiation of Aflibercept)~* Refractory to ranibizumab (defined by persistent fluid despite a treatment conducted according to the HAS French recommendations with at least 3 loading doses injections)~* Patient who switched to aflibercept (Eylea) between 1st of January 2014 and 30th June 2015~* Written informed consent given~Exclusion Criteria:~* Patient who do not meet the local indication criteria for aflibercept treatment. Contraindications listed in the local SmPC (Summary of Product Characteristics) have to be considered~* Recurrent patients with wAMD previously treated with ranibizumab and switched to aflibercept because of a high recurrence rate (recurrent patients described by Yonegawa et al.in AJO (American Journal of Ophthalmology )2013= exudation suppressed but high rate of injections)~* Patient who have been previously treated by any macular laser Visudyne/PD (Photodynamic therapy)~* Patient with a Visual Acuity (VA) \<1/10~* Patient with Fibrosis involving Macula~* Patient with atrophic AMD~* Patient with any other retinal disease as myopia, diabetic retinopathy, diabetic macular oedema,chorioretinal anastomosis (CRA),, angioid streaks~* Patients taking part in an interventional study at the time of enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled to undergo non-myeloablative allogeneic stem-cell transplantation.~* meet institutional eligibility criteria for allogeneic SCT. Significant criteria are:~  * Renal function: Serum creatinine \<2; or calculated creatinine clearance \> 40 mL/min/1.72m2;~ * Hepatic function: Baseline direct bilirubin, ALT or AST lower than three times the upper limit of normal;~ * Pulmonary disease: FVC or FEV1 \> 40% predicted; Cardiac ejection fraction \> 40%.~Exclusion Criteria:~* Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant~* Patients who are not undergoing standard non-myeloablative SCT with Flu/Bu conditioning and Tax/MTX GVHD prophylaxis~* Patients with uncontrolled bacterial, viral or fungal infections~* Patients who take strong inducers or inhibitors of the CYP450A4~* Patients receiving other investigational drugs for GVHD~* Women who are pregnant, plan to become pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: 150mg Maraviroc (Type: EXPERIMENTAL): 150mg twice daily
- Phase 1: 300mg Maraviroc (Type: EXPERIMENTAL): 300mg twice daily
- Phase 2: 300mg Maraviroc (Type: EXPERIMENTAL): 300mg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with end stage renal disease (stage CKD 5d), receiving stable subcutaneous maintenance therapy with Epogen® or Procrit® at least once per week~* Mean hemoglobin level between 9.0 - 11.5 g/dL during the screening period~* Adequate iron substitution~Exclusion Criteria:~* Contraindications for Erythropoiesis Stimulating Agent (ESA) therapy~* History of Pure Red Cell Aplasia (PRCA), or anti-erythropoietin (EPO) antibodies~* Known Human Immunodeficiency Virus (HIV) or Hepatitis B infection~* Hepatitis C infection on an active treatment~* Symptomatic congestive heart failure (New York Heart Association \[NYHA\] class III and IV)~* Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization~* Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months prior to randomization~* History of malignancy of any organ system~* Systemic lupus erythematous~* Immunocompromized patients~Other In-/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HX575 epoetin alfa (Type: EXPERIMENTAL): HX575, recombinant human epoetin alfa
- US-licensed epoetin alfa (Type: ACTIVE_COMPARATOR): US-licensed recombinant human epoetin alfa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria consists of all patients suffering from HD at an age of less than 13 years old, and HD is confirmed by postoperative pathological examination, barium enema and anorectal manometry.~Exclusion Criteria:~* Age\> 13 years old~* Patients are complicated with mental, neurological disorders (such as hypoxic-ischemic encephalopathy, epilepsy and dementia) or can not thrive.~* Patients are complicated with congenital gastrointestinal malformations (such as anal stenosis, intestinal atresia stenosis), metabolic and endocrine diseases caused by organic constipation and functional constipation in children.~* Children are complicated with liver, kidney dysfunction, blood disorders, immune deficiency diseases and significant ECG abnormalities.~* Children have taken oral antibiotics, microecological modulator, yogurt, other gastrointestinal motility drugs which can affect the gut flora.~* Drug allergies, or allergic diseases..~* Poor compliance with oral probiotics treatment.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.~* Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.~* Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.~* (For sub-study) Currently participating in open ended assessment period of main study 2993 LAR105~Exclusion Criteria:~* Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog.~* Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.~* Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:~  * Alpha glucosidase inhibitor or meglitinide within 30 days of screening;~ * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;~ * Regular use (\> 14 days) of drugs that directly affect gastrointestinal motility;~ * Regular use (\> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;~ * Regular use (\> 14 days) of medications with addictive potential such as opiates and opioids;~ * Prescription or over-the-counter weight loss medications within 6 months of screening.~* (For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly (Type: EXPERIMENTAL): Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
- Exenatide Twice Daily (Type: ACTIVE_COMPARATOR): subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, of any race, at least 18 years of age (inclusive).~* Freely provides both verbal and written informed consent.~* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.~* Subject is willing to comply with study instructions and return to the clinic for required visits.~Key Exclusion Criteria:~* Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator.~* Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator.~* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator.~* Is pregnant, nursing an infant, or planning a pregnancy during the study period.~* Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IDP-122 Lotion (Type: EXPERIMENTAL): Lotion
- Ultravate Cream (Type: ACTIVE_COMPARATOR): Cream
- IDP-122 Vehicle Lotion (Type: ACTIVE_COMPARATOR): Lotion
- IDP-122 Vehicle Cream (Type: ACTIVE_COMPARATOR): Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Identified PKU by newborn screening; started diet treatment before 1 mo age~* Diagnosis of classical or variant PKU with documented phenylalanine level of greater than 600 umol/L at 7-10d of age~* Follows or willing to follow PKU diet and consume amino acid medical formula providing more than 50% of protein needs~* Acceptance of glycomacropeptide foods determined prior to enrollment~Exclusion Criteria:~* Females who are pregnant or planning pregnancy~* Individuals with mental deficits due to untreated or poorly controlled PKU~* Individuals with any health condition deemed to interfere with participation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GMP Diet/GMP Medical Foods (Type: EXPERIMENTAL): The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
- AA Diet/AA Medical Foods (Type: ACTIVE_COMPARATOR): The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete